Journal of Clinical Oncology, Vol 24, No 8 (March 10), 2006: pp. 1281-1288
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.8819
Primary CNS Lymphoma
Tracy Batchelor,
Jay S. Loeffler
From the Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Division of Neuro-Oncology, Department of Neurology, and Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Address reprint requests to Tracy Batchelor, MD, MPH, Yawkey 9E, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114; e-mail: tbatchelor{at}partners.org
Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased in incidence during the last three decades and occurs in both immunocompromised and immunocompetent hosts. PCNSL in immunocompetent patients is associated with unique diagnostic, prognostic, and therapeutic issues, and the management of this malignancy is different from that of other forms of extranodal NHL. Characteristic imaging features should be suggestive of the diagnosis, avoidance of corticosteroids, if possible, and early neurosurgical consultation for stereotactic biopsy. Because PCNSL may involve the brain, CSF, and eyes, diagnostic evaluation should include assessment of all of these regions as well as screening for possible occult systemic disease. Resection provides no therapeutic benefit and should be reserved for the rare patient with neurologic deterioration due to brain herniation. Whole-brain radiation therapy (WBRT) alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients older than age 60. Neurotoxicity typically is associated with significant cognitive, motor, and autonomic dysfunction, and has a negative impact on quality of life. Chemotherapy and WBRT together improve tumor response rates and survival compared with WBRT alone. Methotrexate-based multiagent chemotherapy without WBRT is associated with similar tumor response rates and survival compared with regimens that include WBRT, although controlled trials have not been performed. The risk of neurotoxicity is lower in patients treated with chemotherapy alone.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
W. Huh, J. Ho Han, C.-K. Park, and S.-H. Park
Primary CNS Lymphoma Presenting With Acute Blindness and Encephalocele
J. Clin. Oncol.,
February 1, 2008;
26(4):
678 - 679.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Vicuna-Kojchen, S Frenkel, T Siegal, E Shalom, I Chowers, and J Pe'er
Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
Br. J. Ophthalmol.,
February 1, 2008;
92(2):
231 - 235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al.
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Blood,
February 1, 2008;
111(3):
1085 - 1093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood,
July 1, 2007;
110(1):
29 - 36.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Booman, J. Douwes, M.-C. Legdeur, J. van Baarlen, E. Schuuring, and P. Kluin
From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective out-growth in two immune sanctuariesy
Haematologica,
June 1, 2007;
92(6):
e69 - e71.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt
Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma
Clin. Cancer Res.,
April 15, 2007;
13(8):
2504 - 2511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Lawrence, J. C. Buckner, and F. F. Lang
CNS Malignancies: At Last, Real Progress
J. Clin. Oncol.,
March 10, 2006;
24(8):
1225 - 1227.
[Full Text]
[PDF]
|
 |
|
|